Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.

Cancer chemotherapy and pharmacology - 1 May 2004

Hsiao Hui-Hua, Yang Ming-Yu, Chang Jan-Gowth, Liu Yi-Chang, Liu Ta-Chih, Chang Chao-Sung, Chen Tyen-Po, Lin Sheng-Fung

Abstract excerpt

BACKGROUND/PURPOSE: 5-Fluorouracil (5-FU) remains the most frequently used chemotherapy agent in various human cancers. Over 80% of the 5-FU administered is metabolized by dihydropyrimidine dehydrogenase (DPD) in the liver. However, mutations in the DPD gene have been found to be associated with low DPD activity causing severe complications. The aim of this study was to determine the frequency of 11 known...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dihydrouracil Dehydrogenase (NADP)
Share to DNA, Complementary

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunosorbent Assay

Share to DPYD gene

Share to Mutation

Share to Pharmacogenetics

Share to Polymerase Chain Reaction

Share to Polymorphism, Restriction Fragment Length

Source

Identifiers

PMID: 15132136
DOI: 10.1007/s00280-003-0749-y

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.PMID 15132136Read ↗

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Semantic proximity Read ↗

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Semantic proximity Read ↗

[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.Semantic proximity Read ↗

Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.Semantic proximity Read ↗

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.Semantic proximity Read ↗

Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.Semantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.Semantic proximity Read ↗

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.